Abstract:Objective: To analyze therapeutic drug monitoring of vancomycin in our hospital at 2015, and to provide evidence for clinical individualized medication. Methods: Statistical analysis was conducted on general information, original illness, pathogen detection result, plasma concentration and renal function which derived from 149 cases of patients with blood concentration monitoring of vancomycin. Results: The therapeutic drug monitoring rate was 13.26%. The blood trough concentration during 10-20 μg?mL-1 accounted for 41.23%. Before and after treatment renal dysfunction rate were 27.52% and 30.87% respectively. Conclusion: Vancomycin therapeutic drug monitoring results were mainly normal in most of our patients our hospital, but there were still some aberrant testing results. The dosage of vancomycin should be adjusted according to clinical reality.
[1] Chen Y L, Chen K, Ye Z K, et al. Development of Chinese Practice Guidelines on Therapeutic Drug Monitoring of Vancomycin[J]. Chin J Evid-based Med, 2015, 15(2): 236-239.
[2] Staatz C E, Byrne C, Thomson A H. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery[J]. Brit J Clin Pharmacol, 2006, 61(2):164-176.
[3] Hutschala D, Kinstner C, K Skhirdladze, et al. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion[J]. Anesthesiology, 2009, 111(2):356-365.
[4] Rybak M1, Lomaestro B, Rotschafer J C, et al. Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists[J]. Am J Health Syst Pharm, 2009, 66(1):82-98.
[5] Jones R N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/ static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains[J]. Clin Infect Dis, 2006, 42(Supply):S13-S24.
[6] Sakoulas G, Eliopoulos G M, Fowler V G Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function[J]. Antimicrob Agents Chemother, 2005, 49(7): 2687-2692.
[7] Tsuji B T, Rybak M J, Cheung C M, et al. Community and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents[J]. Diagn Microbiol Infect Dis, 2007, 58(1):41-47.
[8] 万古霉素临床应用剂量专家组.《万古霉素临床应用剂量中国专家共识》[J]. 中华传染病杂志, 2012, 30(11):641.
[9] 胡云建. 临床主要耐药菌流行趋势[J]. 临床药物治疗杂志, 2010, 3(8):4-8.